Journey Medical Corp

DERM

Journey Medical Corp

DERM

Insider Sentiment (TTM):

Last Purchase:2024-03-25Last Sale:2025-05-02Shares Purchased (TTM):0Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:11,754,203Shares Outstanding:27,305,028Institutional Ownership Pct.:43.05%

Earnings Market Reaction:

Filing Date:2026-08-12Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Common Excluding Class	-	0	0	0	0	0	0	1	0	14	13	0
Debt Instrument Unamortized Discount Noncurrent	-	-	-	-	-	-	-	-	-	-	-	0
Common Class A	-	6	6	0	0	6	6	0	0	6	6	0
Common Stock Par Or Stated Value Per Share	-	-	0	-	-	-	0	-	-	-	0	-
Common Stock Shares Authorized	-	-	50	-	-	-	50	-	-	-	50	-
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	26	27	24	25	20	21	20	22	24	24	27	25
Accounts Receivable Net Current	36	25	30	18	16	18	10	11	10	10	15	8
Inventory Net	8	9	10	12	13	12	14	12	10	11	10	11
Prepaid Expense And Other Assets Current	3	3	3	2	2	2	3	1	2	3	4	1
Assets Current	73	65	67	56	51	54	48	46	46	47	56	45
Intangible Assets Net Excluding Goodwill	26	26	28	29	30	31	32	18	19	19	20	21
Operating Lease Right Of Use Asset	0	0	0	0	0	0	0	0	0	0	0	0
Other Assets Noncurrent	-	-	-	-	-	-	-	0	0	0	0	0
Assets	98	92	95	85	81	85	80	64	65	67	77	66
Liabilities And Stockhold…
Liabilities
Liabilities Current
Accounts Payable Current	8	8	9	12	13	14	16	15	15	15	18	28
Other Liabilities Current	0	0	0	1	1	0	1	0	0	0	0	1
Accrued Liabilities Current	32	26	28	21	23	23	17	16	16	20	20	16
Interest Payable Current	0	0	0	0	0	0	0	0	0	0	0	-
Accrued Income Taxes Current	-	0	0	0	0	0	0	-	-	0	0	0
Long Term Debt Current	5	3	-	6	4	2	-	-	-	-	-	-
Operating Lease Liability Current	0	0	0	0	0	0	0	0	0	0	0	0
Liabilities Current	46	38	37	40	40	40	35	33	34	39	42	49
Long Term Debt Noncurrent	20	23	25	20	21	23	25	20	20	15	15	-
Operating Lease Liability Noncurrent	-	-	0	0	0	0	0	-	-	-	0	0
Liabilities	66	61	63	59	62	63	60	53	54	54	56	49
Stockholders Equity
Additional Paid In Capital	133	132	130	123	114	113	107	99	97	96	93	88
Retained Earnings Accumulated Deficit	-101	-101	-98	-97	-95	-91	-87	-89	-86	-83	-72	-70
Stockholders Equity	32	31	32	26	19	22	20	11	11	13	20	17
Liabilities And Stockholders Equity	98	92	95	85	81	85	80	64	65	67	77	66

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	15.03%	36.61%	24.28%	-	-	-	-	-	-	-	-	-
2025	4.08%	0.00%	-1.55%	-17.92%	-14.17%	-4.92%	-12.67%	-17.95%	-7.93%	12.76%	32.43%	32.64%
2024	30.19%	44.32%	44.88%	-2.90%	35.48%	28.01%	-1.83%	-21.83%	-16.51%	5.57%	17.15%	14.53%
2023	-	-	-	-	-	-	46.60%	27.20%	21.41%	-	-	-
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	1.59	1.72	1.79	1.42	1.27	1.34	1.37	1.38	1.36	1.21	1.35	0.92
Quick Ratio	1.35	1.38	1.44	1.08	0.89	0.97	0.87	0.99	1.01	0.87	1.02	0.67
Working Capital	27.01M	27.14M	29.43M	16.67M	10.79M	13.76M	13.00M	12.83M	12.32M	8.08M	14.59M	-3.82M
Leverage & Debt
Debt to Equity	2.06	1.97	1.97	2.29	3.22	2.94	3.00	4.86	4.77	4.14	2.78	2.79
Interest Coverage TTM	-0.82	-1.71	-2.21	-1.53	-2.01	-2.27	-5.07	-9.52	1.51	-1.63	-1.22	-4.35
Debt Ratio	0.67	0.66	0.66	0.70	0.76	0.75	0.75	0.83	0.83	0.81	0.74	0.74
Efficiency & Turnover
Asset Turnover TTM	0.75	0.73	0.71	0.79	0.77	0.74	0.71	0.59	0.87	0.74	0.66	0.95
Days Sales Outstanding TTM	140.27	121.38	118.05	88.95	84.49	90.28	82.75	88.54	85.05	112.90	132.85	81.03
Receivables Turnover TTM	2.60	3.01	3.09	4.10	4.32	4.04	4.41	4.12	4.29	3.23	2.75	4.50
Per Share Metrics
Diluted EPS TTM	-0.22	-0.35	-0.47	-0.35	-0.38	-0.37	-0.72	-0.89	0.04	-0.21	-0.21	-0.59
Free Cash Flow Per Share TTM	-0.48	-0.25	-0.51	-0.04	0.01	-0.31	-0.45	-1.36	-0.40	0.06	0.01	0.70
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	-	-	-	69.86%	69.41%	66.48%	62.81%	45.69%	62.25%	61.54%	61.63%	65.52%
Operating Profit Margin TTM	-4.46%	-9.80%	-13.21%	-9.35%	-12.16%	-12.29%	-24.36%	-46.84%	3.64%	-4.30%	-3.47%	-12.11%
Net Profit Margin TTM	-9.04%	-14.82%	-18.48%	-14.73%	-15.49%	-14.76%	-26.14%	-47.67%	1.44%	-6.88%	-6.46%	-15.02%
Growth Metrics
Net Revenue Growth (1Y)	19.70%	15.00%	10.20%	52.86%	-3.39%	-7.00%	-5.91%	-53.24%	-8.44%	-7.08%	-19.01%	-16.63%
Net Income Growth (1Y)	-30.14%	15.48%	-22.09%	-52.75%	-1,136.54%	99.64%	280.79%	48.45%	-102.15%	-89.17%	-87.00%	-76.40%
EPS Growth (1Y)	-40.82%	-4.38%	-35.02%	-61.12%	-989.81%	74.44%	239.81%	33.11%	-101.94%	-90.23%	-87.50%	-77.42%
Valuation Metrics
P/E TTM	-31.89	-13.36	-16.52	-20.51	-19.14	-16.07	-5.44	-6.33	133.77	-17.48	-27.26	-4.09
P/B TTM	6.06	4.15	5.93	6.86	8.69	6.19	3.98	10.62	9.98	5.61	5.16	2.90
P/S TTM	2.88	1.98	3.05	3.02	2.97	2.37	1.42	3.02	1.93	1.20	1.76	0.61
Market Cap	194.66M	128.06M	188.88M	177.71M	167.23M	133.41M	79.89M	116.04M	112.77M	72.71M	105.02M	50.46M
Enterprise Value	194.48M	126.21M	190.07M	177.92M	172.05M	137.32M	84.46M	113.36M	108.60M	63.33M	92.20M	25.71M
Calculated Values
Free Cash Flow TTM	-13.23M	-6.70M	-12.44M	-1.10M	126.00K	-6.94M	-9.13M	-27.87M	-7.97M	1.18M	240.00K	12.92M
Net Debt	-171.00K	-1.85M	1.19M	211.00K	4.82M	3.91M	4.57M	-2.68M	-4.16M	-9.37M	-12.82M	-24.75M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2025-05-02Sale

Owner: Benesch, Joseph

Title: CFO

Shares: 2,409

Price/Share: $6.84

Value: $16,477.56

Shares Owned: 203,557

Relationship: Officer

Ownership: Direct

2025-05-02Sale

Owner: Maraoui, Claude

Title: President & CEO

Shares: 4,834

Price/Share: $6.84

Value: $33,064.56

Shares Owned: 2,348,313

Relationship: Director,Officer

Ownership: Direct

2025-05-02Sale

Owner: Alloush, Ramsey

Title: COO

Shares: 2,857

Price/Share: $6.84

Value: $19,541.88

Shares Owned: 504,817

Relationship: Officer

Ownership: Direct

2025-03-11Sale

Owner: Maraoui, Claude

Title: President & CEO

Shares: 49,271

Price/Share: $5.01

Value: $246,847.71

Shares Owned: 2,003,147

Relationship: Director,Officer

Ownership: Direct

2025-03-07Sale

Owner: Maraoui, Claude

Title: President & CEO

Shares: 14,905

Price/Share: $5.01

Value: $74,674.05

Shares Owned: 2,052,418

Relationship: Director,Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2025-05-02	Benesch, Joseph	Officer	CFO	Direct	Sale	2,409	6.84	$16,477.56	203,557	4
2025-05-02	Maraoui, Claude	Director,Officer	President & CEO	Direct	Sale	4,834	6.84	$33,064.56	2,348,313	4
2025-05-02	Alloush, Ramsey	Officer	COO	Direct	Sale	2,857	6.84	$19,541.88	504,817	4
2025-03-11	Maraoui, Claude	Director,Officer	President & CEO	Direct	Sale	49,271	5.01	$246,847.71	2,003,147	4
2025-03-07	Maraoui, Claude	Director,Officer	President & CEO	Direct	Sale	14,905	5.01	$74,674.05	2,052,418	4
2025-03-05	Maraoui, Claude	Director,Officer	President & CEO	Direct	Sale	18,147	5.13	$93,094.11	2,092,874	4
2025-02-21	Benesch, Joseph	Officer	CFO	Direct	Sale	1,365	5.19	$7,084.35	45,966	4
2024-08-01	Benesch, Joseph	Officer	CFO	Direct	Sale	9,324	5.47	$51,002.28	47,331	4
2024-07-23	Benesch, Joseph	Officer	CFO	Direct	Sale	4,055	5.40	$21,897.00	56,655	4
2024-03-25	Rosenwald, Lindsay A Md	Director	-	Direct	Purchase	10,000	3.04	$30,400.00	144,245	4
2024-03-22	Rosenwald, Lindsay A Md	Director	-	Direct	Purchase	20,000	3.40	$68,000.00	134,245	4
2024-03-22	Maraoui, Claude	Director,Officer	President & CEO	Direct	Purchase	10,000	3.48	$34,800.00	2,163,430	4
2024-03-22	Smith, Justin Adam	Director	-	Direct	Purchase	30,000	3.47	$104,100.00	134,717	4
2024-02-22	Benesch, Joseph	Officer	Interim CFO	Direct	Sale	2,450	3.75	$9,187.50	60,710	4
2023-11-28	Paley, Jeffrey	Director	-	Direct	Sale	1,745	5.22	$9,108.90	70,727	4
2023-11-08	Paley, Jeffrey	Director	-	Direct	Sale	255	3.76	$958.80	114,217	4
2023-10-13	Smith, Justin Adam	Director	-	Direct	Purchase	33,000	2.98	$98,340.00	104,717	4
2023-10-06	Paley, Jeffrey	Director	-	Direct	Purchase	15,000	2.98	$44,700.00	72,472	4
2023-09-21	Paley, Jeffrey	Director	-	Direct	Purchase	30,000	2.97	$89,100.00	57,472	4
2023-09-06	Rosenwald, Lindsay A Md	Director	-	Direct	Purchase	100,000	2.23	$223,000.00	114,245	4
2023-09-06	Maraoui, Claude	Director,Officer	President & CEO	Direct	Purchase	26,044	2.52	$65,630.88	2,153,430	4
2023-07-24	Maraoui, Claude	Director,Officer	President & CEO	Direct	Sale	20,767	1.76	$36,549.92	2,127,386	4
2023-07-24	Benesch, Joseph	Officer	See Remarks	Direct	Sale	4,072	1.76	$7,166.72	63,160	4
2023-05-17	Maraoui, Claude	Director,Officer	President & CEO	Direct	Sale	24,377	1.34	$32,665.18	2,148,153	4
2023-02-22	Benesch, Joseph	Officer	Interim CFO	Direct	Sale	2,768	1.97	$5,452.96	67,232	4
2022-10-04	De, Paolantonio Ernest Ro…	Officer	See Remarks	Direct	Sale	10,093	2.41	$24,324.13	259,907	4/A
2022-10-04	De, Paolantonio Ernest Ro…	Officer	Chief Financial Officer	Direct	Sale	10,093	2.41	$24,324.13	259,907	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

43.05%

Inst. Shares: 11,754,203

Shares Outstanding: 27,305,028

2025-12-31

44.63%

Inst. Shares: 10,932,956

Shares Outstanding: 24,497,973

2025-09-30

33.94%

Inst. Shares: 8,470,082

Shares Outstanding: 24,959,114

2025-06-30

26.66%

Inst. Shares: 6,210,162

Shares Outstanding: 23,290,806

2024-06-30

8.00%

Inst. Shares: 1,600,424

Shares Outstanding: 19,993,858

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	11,754,203	27,305,028	43.05%
2025-12-31	10,932,956	24,497,973	44.63%
2025-09-30	8,470,082	24,959,114	33.94%
2025-06-30	6,210,162	23,290,806	26.66%
2024-06-30	1,600,424	19,993,858	8.00%
2024-03-31	1,118,414	19,757,449	5.66%
2023-12-31	700,598	18,232,422	3.84%
2023-09-30	1,710,496	18,416,368	9.29%
2023-06-30	1,235,347	18,005,055	6.86%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Journey Medical Corp (DERM) — SEC Financial Statements & Analysis

Journey Medical Corp (DERM) is a pharmaceutical preparations company, incorporated in DE. Journey Medical Corp trades on Nasdaq as: DERM. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Journey Medical Corp reported a 19.70% year-over-year revenue growth, a Gross Profit Margin of 69.86% (TTM), a Debt-to-Equity ratio of 2.06x, a Price-to-Sales (P/S) ratio of 2.88x (TTM), a Price-to-Book (P/B) ratio of 6.06x (TTM), at a market cap of $194.66M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 19.70%
Gross Profit Margin TTM: 69.86%
Debt To Equity: 2.06x
P/S TTM: 2.88x
P/B TTM: 6.06x
Market Cap: $194.66M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Journey Medical Corp in?

Journey Medical Corp (DERM) operates in the Pharmaceutical Preparations industry.

What is DERM's market cap?

Journey Medical Corp (DERM) has a market capitalization of $194.66M as of 2026-06-30.

What exchange does DERM trade on?

Journey Medical Corp (DERM) trades on the Nasdaq.

Where is Journey Medical Corp incorporated?

Journey Medical Corp is incorporated in DE.